Tenax Therapeutics Company Profile (NASDAQ:TENX)

About Tenax Therapeutics (NASDAQ:TENX)

Tenax Therapeutics logoTenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TENX
  • CUSIP: N/A
  • Web: www.tenaxthera.com
Capitalization:
  • Market Cap: $10.31 million
  • Outstanding Shares: 28,236,000
Average Prices:
  • 50 Day Moving Avg: $0.36
  • 200 Day Moving Avg: $0.52
  • 52 Week Range: $0.31 - $2.65
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.30
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.40 per share
  • Price / Book: 0.91
Profitability:
  • EBIDTA: ($15,350,000.00)
  • Return on Equity: -66.67%
  • Return on Assets: -51.43%
Debt:
  • Current Ratio: 4.12%
  • Quick Ratio: 4.12%
Misc:
  • Average Volume: 379,544 shs.
  • Beta: 1.23
  • Short Ratio: 3.73
 

Frequently Asked Questions for Tenax Therapeutics (NASDAQ:TENX)

What is Tenax Therapeutics' stock symbol?

Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) announced its quarterly earnings data on Tuesday, December, 15th. The company reported ($0.13) EPS for the quarter, beating the Zacks' consensus estimate of ($0.14) by $0.01. View Tenax Therapeutics' Earnings History.

Where is Tenax Therapeutics' stock going? Where will Tenax Therapeutics' stock price be in 2017?

1 brokerages have issued twelve-month price objectives for Tenax Therapeutics' stock. Their predictions range from $2.50 to $2.50. On average, they expect Tenax Therapeutics' share price to reach $2.50 in the next twelve months. View Analyst Ratings for Tenax Therapeutics.

Who are some of Tenax Therapeutics' key competitors?

Who are Tenax Therapeutics' key executives?

Tenax Therapeutics' management team includes the folowing people:

  • Ronald R. Blanck, Independent Chairman of the Board
  • Michael B. Jebsen CPA, President, Interim Chief Executive Officer, Chief Financial Officer
  • Douglas Hay Ph.D., Executive Vice President - Regulatory Affairs
  • Doug Randall, Executive Vice President - Business and Commercial Operations
  • Paula Bokesch, Chief Medical Officer
  • James Mitchum, Director
  • Gerald T. Proehl, Director
  • Anthony DiTonno, Independent Director
  • Gregory Pepin, Independent Director
  • Chris A. Rallis, Independent Director

Who owns Tenax Therapeutics stock?

Tenax Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.60%) and Bank of New York Mellon Corp (0.50%). Company insiders that own Tenax Therapeutics stock include Gerald T Proehl and Ronald R Blanck. View Institutional Ownership Trends for Tenax Therapeutics.

Who sold Tenax Therapeutics stock? Who is selling Tenax Therapeutics stock?

Tenax Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Tenax Therapeutics.

Who bought Tenax Therapeutics stock? Who is buying Tenax Therapeutics stock?

Tenax Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. Company insiders that have bought Tenax Therapeutics stock in the last two years include Gerald T Proehl and Ronald R Blanck. View Insider Buying and Selling for Tenax Therapeutics.

How do I buy Tenax Therapeutics stock?

Shares of Tenax Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tenax Therapeutics' stock price today?

One share of Tenax Therapeutics stock can currently be purchased for approximately $0.37.


MarketBeat Community Rating for Tenax Therapeutics (NASDAQ TENX)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  16 (Vote Underperform)
Total Votes:  51
MarketBeat's community ratings are surveys of what our community members think about Tenax Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Tenax Therapeutics (NASDAQ:TENX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.50 (584.93% upside)

Analysts' Ratings History for Tenax Therapeutics (NASDAQ:TENX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017Ladenburg Thalmann Financial ServicesUpgradeNeutral -> Buy$2.50HighView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Tenax Therapeutics (NASDAQ:TENX)
Earnings by Quarter for Tenax Therapeutics (NASDAQ:TENX)
Earnings History by Quarter for Tenax Therapeutics (NASDAQ TENX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016Q316($0.17)($0.15)ViewListenView Earnings Details
12/15/2015Q216($0.14)($0.13)ViewListenView Earnings Details
9/14/2015Q116($0.14)($0.11)ViewListenView Earnings Details
7/16/2015Q415($0.14)($0.18)ViewListenView Earnings Details
3/18/2015Q315($0.16)($0.10)ViewN/AView Earnings Details
12/17/2014Q215($0.18)($0.14)ViewN/AView Earnings Details
3/17/2014($0.38)($0.13)$0.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tenax Therapeutics (NASDAQ:TENX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.09)($0.09)($0.09)
Q3 20171($0.04)($0.04)($0.04)
Q4 20171($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tenax Therapeutics (NASDAQ:TENX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Tenax Therapeutics (NASDAQ:TENX)
Insider Ownership Percentage: 9.81%
Institutional Ownership Percentage: 6.56%
Insider Trades by Quarter for Tenax Therapeutics (NASDAQ:TENX)
Insider Trades by Quarter for Tenax Therapeutics (NASDAQ:TENX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/23/2016Gerald T ProehlDirectorBuy29,882$1.67$49,902.94View SEC Filing  
11/19/2015Ronald R BlanckDirectorBuy4,700$3.26$15,322.00View SEC Filing  
1/20/2015Ronald R BlanckDirectorBuy2,000$3.49$6,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Tenax Therapeutics (NASDAQ:TENX)
Latest Headlines for Tenax Therapeutics (NASDAQ:TENX)
Source:
DateHeadline
bizjournals.com logoHow These Biotech Stocks are Performing? -- Agenus, Aptose Biosciences, RXi Pharma, and Tenax Therapeutics
www.bizjournals.com - August 4 at 8:54 AM
finance.yahoo.com logoTENX: FDA Response on Levosimendan
finance.yahoo.com - August 3 at 7:52 AM
finance.yahoo.com logoTenax Therapeutics Provides Regulatory Update on Levosimendan
finance.yahoo.com - July 29 at 7:50 AM
americanbankingnews.com logoZacks Investment Research Weighs in on Tenax Therapeutics Inc's FY2017 Earnings (TENX)
www.americanbankingnews.com - May 19 at 7:56 AM
americanbankingnews.com logoTenax Therapeutics Inc (TENX) Upgraded at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - May 18 at 8:34 AM
americanbankingnews.com logoTenax Therapeutics Inc Forecasted to Post Q2 2017 Earnings of ($0.09) Per Share (TENX)
www.americanbankingnews.com - May 18 at 7:54 AM
streetinsider.com logoTenax Therapeutics (TENX) Reviews Additional Data with FDA & Potential Levosimendan NDA Submission
www.streetinsider.com - May 16 at 8:10 PM
finance.yahoo.com logoTenax Meets with FDA to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission
finance.yahoo.com - May 16 at 8:10 PM
finance.yahoo.com logoTenax CEO resigns, company to review 'strategic alternatives'
finance.yahoo.com - April 10 at 7:42 PM
streetinsider.com logoTenax Therapeutics (TENX) to Review Strategic Alternatives; CEO Resigns
www.streetinsider.com - April 7 at 11:21 PM
streetinsider.com logoTenax Therapeutics (TENX) to Review Strategic Alternatives; CEO Resigns - StreetInsider.com
www.streetinsider.com - April 7 at 12:58 PM
finance.yahoo.com logoTenax Therapeutics Announces Review of Strategic Alternatives and Business Update
finance.yahoo.com - April 7 at 12:58 PM
finance.yahoo.com logoTENX: 2016 Results; Subgroup Analysis Shows CABG Survival Benefit
finance.yahoo.com - March 27 at 7:24 PM
finance.yahoo.com logoTENAX THERAPEUTICS, INC. Financials
finance.yahoo.com - March 22 at 8:05 PM
streetinsider.com logoTenax Therapeutics (TENX) Offers FY16 Results, Corporate Update
www.streetinsider.com - March 22 at 12:57 AM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Banks, Chipotle, Airlines, Pain Therapeutics, Pulmatrix, Sunshine Heart - Nasdaq
www.nasdaq.com - March 21 at 7:54 PM
streetinsider.com logoTenax Therapeutics (TENX) Offers FY16 Results, Corporate Update - StreetInsider.com
www.streetinsider.com - March 21 at 7:54 PM
finance.yahoo.com logoTenax Therapeutics Announces Year-End 2016 Financial Results and Provides Corporate Update
finance.yahoo.com - March 21 at 9:57 AM
biz.yahoo.com logoQ4 2016 Tenax Therapeutics Inc Earnings Release - Before Market Open
biz.yahoo.com - March 21 at 9:57 AM
finance.yahoo.com logoInvestor Network Invites You to the Tenax Therapeutics Fiscal Year 2016 Business Review and Update Conference Call and Webcast on Tuesday, March 21, 2017
finance.yahoo.com - March 20 at 6:18 PM
biz.yahoo.com logoTENAX THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St
biz.yahoo.com - March 17 at 8:13 PM
biz.yahoo.com logoTENAX THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 9:13 PM
finance.yahoo.com logoTenax Therapeutics to Discuss Year-End 2016 Financial Results and Provide Business Update
finance.yahoo.com - March 15 at 9:27 PM
finance.yahoo.com logoTENX: Tenax Reports LEVO-CTS Topline Results
finance.yahoo.com - February 9 at 6:06 AM
rttnews.com logoTenax Therapeutics Inc. (TENX) Plummeted To A New Low On Study Results - RTT News
www.rttnews.com - February 3 at 6:11 AM
rttnews.com logoTenax Therapeutics Inc. (TENX) Has Plunged To A New Low On Phase 3 Study News
www.rttnews.com - February 2 at 5:55 AM
us.rd.yahoo.com logo9:00 am Tenax Therapeutics announces top-line results from its Phase 3 LEVO-CTS trial; study did not achieve statistically significant reductions in dual or quad primary endpoints (shares halted)
us.rd.yahoo.com - February 2 at 5:55 AM
us.rd.yahoo.com logoTenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery
us.rd.yahoo.com - February 2 at 5:55 AM
streetinsider.com logoTenax Therapeutics (TENX) Says Phase 3 LEVO-CTS Trial in Cardiac Surgery Did Not Achieve Dual Endpoint - StreetInsider.com
www.streetinsider.com - February 1 at 6:52 AM
rttnews.com logoTenax Therapeutics: Will It Or Won't It?
www.rttnews.com - January 30 at 11:29 AM
finance.yahoo.com logoBiotech M&A Activity Expected to Rise in 2017: Latest Reports on Tenax Therapeutics and ZIOPHARM Oncology
finance.yahoo.com - January 30 at 11:28 AM
finance.yahoo.com logoTenax Therapeutics, Inc. Review of Clinical Trials and Financials
finance.yahoo.com - January 11 at 5:59 AM

Social

Chart

Tenax Therapeutics (TENX) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff